BioLineRx Ltd.

NASDAQ•BLRX

CEO: Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA

セクター: Healthcare

業種: Biotechnology

上場日: 2011-07-27

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

連絡先情報

Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, 7177871, Israel

972-8-642-9100

www.biolinerx.com

時価総額

$11.57M

PER (TTM)

-3.8

17.5

配当利回り

52週高値

$7.77

52週安値

$2.30

52週レンジ

順位65Top 96.0%

1.6

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$427.00K+0.00%

直近4四半期の推移

EPS

-$0.22+1900.00%

直近4四半期の推移

フリーCF

-$2.11M+0.00%

直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Massive Revenue Jump Total revenues reached $28.9M in 2024, a 502.1% increase, driven by upfront and milestone payments from licensing deals.

Net Loss Significantly Narrows Net loss improved substantially to ($9.2M) in 2024 from ($60.6M) in 2023, reflecting reduced operating expenses post-restructuring.

Successful Capital Raising Net cash provided by financing activities was $20.7M in 2024, supported by registered direct offerings completed in late 2024 and early 2025.

R&D Costs Decreased Research and development expenses fell 26.4% to $9.2M in 2024, following termination of AGI-134 development and US commercial shutdown.

リスク要因

Going Concern Material Uncertainty Management concluded substantial doubt about ability to continue as going concern, despite recent financing efforts providing runway through H2 2026.

Partner Commercialization Dependency Future revenue hinges on licensees (Ayrmid, Gloria) successfully commercializing APHEXDA across licensed territories and indications.

Israeli Geopolitical Instability Operations based in Israel face adverse effects from ongoing political, economic, and military instability in the region, impacting business continuity.

Biokine Arbitration Claim Biokine filed complaint seeking $6.5M damages for alleged breach; dispute referred to arbitration, outcome remains uncertain for proprietary technology rights.

見通し

Cash Runway Secured Existing cash and expected partnership inflows provide sufficient capital requirements through the second half of 2026.

Refocused Israeli Development Operations refocused on development activities in Israel for oncology and rare diseases, achieving a significantly reduced annual cash burn rate.

Pipeline Expansion Strategy Actively pursuing in-licensing opportunities to expand and diversify product pipeline, focusing on assets complementing core expertise in oncology/rare disease.

Future Financing Exploration Expect to continue exploring alternative financing sources, including future securities offerings and government grants, to support ongoing development objectives.

同業比較

売上高 (TTM)

EDIT

$40.52M

+25.4%

BLRX

$12.74M

-42.1%

MREO

$500.00K

-50.0%

粗利益率 (最新四半期)

EDIT

96.7%

+2621.3pp

BLRX

80.3%

+0.0pp

CADL

0.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ANNX	$650.60M	-3.9	-92.3%	11.8%
REPL	$625.90M	-2.2	-102.7%	23.6%
LYEL	$526.32M	-1.5	-90.5%	12.3%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-66.9%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月30日

EPS:-$0.39

売上高:$492.00K

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし